NEW YORK (GenomeWeb News) – Enzo Biochem will seek CLIA waivers for GeneNews' colorectal cancer test in New York and New Jersey and market the test in those states, under an agreement announced by the firms today.

Enzo plans to validate and seek approval in New York, New Jersey, and under CLIA requirements for the ColonSentry blood-based test for colorectal cancer risk. It also intends to market and secure third-party reimbursement for the test. Enzo said it hopes to make the test available in the second half of 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.